logo-loader
ANGLE PLC

ANGLE liquid biopsy used in German breast cancer study

The company’s Parsortix system was used in harness with a device called CellCelector, a micromanipulator, to isolate individual circulating tumour cells

1563778333_shutterstock_130569779.jpg
The company's device has helped researchers glean a greater understanding of breast cancer

ANGLE PLC (LON:AGL, OTCQX:ANPCY) said its liquid biopsy system was used in important work to isolate single circulating tumour cells.

The company’s Parsortix system was used in harness with a device called CellCelector, a micromanipulator.

The idea behind the project, carried out by a team of cancer researchers and clinicians in Duesseldorf, was to assess the “heterogeneity” of the disease.

In layman’s terms, they wanted to know what determined the basis of different strains of the same cancer – in this case breast cancer.

By isolating cancer cells the Duesseldorf team was able to detect varying gene expression between the individual CTCs as well as demonstrating that changes in the patient's HER-2 expression can be detected.

HER-2 advance

Human epidermal growth factor receptor 2, or HER-2, plays an important role in the development of breast cancer.

The detailed results of the research were published in the peer-reviewed journal Cancers.

ANGLE’s chief executive Andrew Newland said:  "This new workflow provides a simple and effective approach to single cell CTC analysis, which is a developing area of research use for the Parsortix system. 

“Investigation of gene expression and HER-2 status in breast cancer will be an important application of Parsortix following FDA [US Food & Drug Administration] clearance."

The shares rose 1% to 71.75p

---adds share price---

Quick facts: ANGLE PLC

Price: £0.71

Market: AIM
Market Cap: £122.66 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Endorsement for Angle's liquid biopsy system Parsortix

Top stories from the Proactive Investors UK newsroom. Angle (LON:AGL) has received an endorsement for its liquid biopsy system Parsortix from European cancer centre UKE, which says it has potential as a biomarker to test for lung cancer. Security group Westminster (LON:WSG) has signed...

on 21/6/19

2 min read